BGNE Stock Overview
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide.
BeiGene, Ltd. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$144.27|
|52 Week High||US$392.30|
|52 Week Low||US$118.18|
|1 Month Change||-13.55%|
|3 Month Change||-24.63%|
|1 Year Change||-57.44%|
|3 Year Change||24.51%|
|5 Year Change||33.52%|
|Change since IPO||409.43%|
Recent News & Updates
EMA panel recommends extending indication for BeiGene's cancer drug Brukinsa
The European Union drug regulator's human medicines committee has recommended extending the indication for BeiGene's (NASDAQ:BGNE) cancer drug Brukinsa, according to the highlights of their latest meeting released on Friday. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended adopting a new indication for Brukinsa as a monotherapy for the treatment of marginal zone lymphoma (MZL). MZL is the second most common non-Hodgkin's lymphoma (NHL), accounting for about seven to eight percent of all NHL cases. Brukinsa was already approved in the European Union for the treatment of Waldenstrom's macroglobulinaemia, a rare type of cancer that begins in the white blood cells. U.S.-listed shares of BeiGene (BGNE) opened 1.4% lower at $158.43.
|BGNE||US Biotechs||US Market|
Return vs Industry: BGNE underperformed the US Biotechs industry which returned -20.8% over the past year.
Return vs Market: BGNE underperformed the US Market which returned -18.2% over the past year.
|BGNE Average Weekly Movement||8.1%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: BGNE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: BGNE's weekly volatility (8%) has been stable over the past year.
About the Company
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin’s lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company’s clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors.
BeiGene, Ltd. Fundamentals Summary
|BGNE fundamental statistics|
Is BGNE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BGNE income statement (TTM)|
|Cost of Revenue||US$1.78b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-19.34|
|Net Profit Margin||-187.65%|
How did BGNE perform over the long term?See historical performance and comparison